Key Insights

Highlights

Success Rate

77% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

19.2%

5 terminated out of 26 trials

Success Rate

77.3%

-9.2% vs benchmark

Late-Stage Pipeline

23%

6 trials in Phase 3/4

Results Transparency

18%

3 of 17 completed with results

Key Signals

3 with results77% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (1)
P 1 (9)
P 2 (8)
P 3 (6)

Trial Status

Completed17
Terminated5
Unknown2
Withdrawn1
Recruiting1

Trial Success Rate

77.3%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT05419518Phase 2Recruiting

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas

NCT00039780Phase 3Completed

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

NCT01115803Phase 1TerminatedPrimary

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

NCT00037869Phase 3Completed

High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

NCT03563326Phase 1Unknown

Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)

NCT03670992Completed

Surgical Treatment of Pancreatic RCC Metastases

NCT02265549CompletedPrimary

Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases

NCT00034697Phase 2TerminatedPrimary

Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)

NCT00046514Phase 2Completed

ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer

NCT00046423Phase 1Completed

A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies

NCT00034918Phase 2Completed

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer

NCT00050336Phase 3Terminated

Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)

NCT00055471Phase 2Completed

A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer

NCT00037609Phase 1Completed

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

NCT00038038Not ApplicableWithdrawn

Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole

NCT01115751Phase 1CompletedPrimary

A Study in Patients With Advanced or Metastatic Cancer

NCT00048893Phase 1Terminated

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

NCT00044863Phase 2Completed

Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma

NCT00065117Phase 2Terminated

Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.

NCT00056173Phase 1Completed

Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

Scroll to load more

Research Network

Activity Timeline